Beryllium's competitive advantage lies in its biology-first, target-centric approach and deep expertise in gene-to-function services. The company leverages its proximity to Boston's biotech ecosystem and maintains a history of successful collaborations with major pharma players. As part of UCB, Beryllium's platform supports discovery programs in immune and central nervous system diseases.
Cyborg Score Rationale
Beryllium operates a specialized and proven drug discovery platform with demonstrated scientific credibility (150+ published articles, 1% of protein data bank contributions). As a UCB subsidiary since June 2017, it benefits from parent company stability and resources but operates within a larger organization, limiting independent growth visibility.
Top Insights
Founded in 1999 with assets from Emerald Bio and deCODE Genetics, combining chemistry and structural biology expertise
Approximately 28 employees as of February 2026, suggesting focused boutique research model
Specialized in gene-to-function services enabling precision medicine and genetic therapy research
Revenue estimated between $1M–$10M annually, indicating niche but sustainable service delivery model
Named Competitors
Charles River Laboratories — Large preclinical and clinical lab services CRO
Envigo — Contract research organization for drug development
Wugen — Protein engineering and structural biology drug discovery
Recent Developments
(June 2017) Acquired by UCB Pharma, Ltd., creating strategic integration with major biopharma partner
(April 2015) Expanded with new 24,000 sq ft research facility in Bedford, MA near Boston biotech hub
(2015–2026) Continued collaboration on drug discovery programs across immune and CNS disease research
Open the full interactive Beryllium, LLC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.